Literature DB >> 27079724

Disruption of White Matter Integrity by Chronic Cerebral Hypoperfusion in Alzheimer's Disease Mouse Model.

Yun Zhai, Toru Yamashita, Yumiko Nakano, Zhuoran Sun, Ryuta Morihara, Yusuke Fukui, Yasuyuki Ohta, Nozomi Hishikawa, Koji Abe.   

Abstract

A rapidly progressing aging society has raised attention to white matter lesions in Alzheimer's disease. In the present study, we applied an AD plus cerebral hypoperfusion (HP) mouse model and investigated the alternation of key protein molecules in the nodal, paranodal, and intermodal sites in the white matter as well as the efficacy of galantamine. Cerebral HP was induced in APP23 mice by bilateral common carotid arteries stenosis with ameroid constrictors. Compared with the wild type and simple APP23 mice, APP23 + HP mice showed a progressive loss of MAG and NF186 from 6 to 12 months, broken misdistribution of MBP, and extended relocation of Nav1.6 and AnkG beyond the primary nodal region in the corpus callosum. Such abnormal neuropathological processes were retrieved with galantamine treatment. The present study demonstrated that cerebral HP strongly disrupted white matter integrity (WMI) at intermodal, paranodal, and Ranvier's nodal sites which may be associated with cognitive decline. Galantamine treatment significantly protected such WMI probably by allosterically potentiating ligand action.

Entities:  

Keywords:  APP23 mice; Alzheimer’s disease; galantamine; hypoperfusion; white matter mater lesion

Mesh:

Substances:

Year:  2016        PMID: 27079724     DOI: 10.3233/JAD-160120

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Chronic Cerebral Hypoperfusion Promotes Amyloid-Beta Pathogenesis via Activating β/γ-Secretases.

Authors:  Zhiyou Cai; Zhou Liu; Ming Xiao; Chuanling Wang; Fuming Tian
Journal:  Neurochem Res       Date:  2017-08-24       Impact factor: 3.996

2.  Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.

Authors:  Tian Feng; Toru Yamashita; Ryo Sasaki; Koh Tadokoro; Namiko Matsumoto; Nozomi Hishikawa; Koji Abe
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-26       Impact factor: 6.200

3.  Tripchlorolide May Improve Spatial Cognition Dysfunction and Synaptic Plasticity after Chronic Cerebral Hypoperfusion.

Authors:  Zhao-Hui Yao; Xiao-Li Yao; Shao-Feng Zhang; Ji-Chang Hu; Yong Zhang
Journal:  Neural Plast       Date:  2019-02-24       Impact factor: 3.599

4.  A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.

Authors:  Koji Abe; Jingwei Shang; Xiaowen Shi; Toru Yamashita; Nozomi Hishikawa; Mami Takemoto; Ryuta Morihara; Yumiko Nakano; Yasuyuki Ohta; Kentaro Deguchi; Masaki Ikeda; Yoshio Ikeda; Koichi Okamoto; Mikio Shoji; Masamitsu Takatama; Motohisa Kojo; Takeshi Kuroda; Kenjiro Ono; Noriyuki Kimura; Etsuro Matsubara; Yosuke Osakada; Yosuke Wakutani; Yoshiki Takao; Yasuto Higashi; Kyoichi Asada; Takehito Senga; Lyang-Ja Lee; Kenji Tanaka
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Identification of a hippocampal lncRNA-regulating network in cognitive dysfunction caused by chronic cerebral hypoperfusion.

Authors:  Zhao-Hui Yao; Jing Wang; Bing-Zhen Shen; Yu-Tong Li; Xiao-Li Yao; Shao-Feng Zhang; Yong Zhang; Ji-Chang Hu; Yan-Chun Xie
Journal:  Aging (Albany NY)       Date:  2020-10-11       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.